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VasopressinPilocarpine (cholinergic muscarinic agonist) injected peripherally may act centrally to produce pressor
responses; in the present study, using c-fos immunoreactive expression, we investigated the forebrain and
brainstem areas activated by pressor doses of intravenous (i.v.) pilocarpine. In addition, the importance of
vasopressin secretion and/or sympathetic activation and the effects of lesions in the anteroventral third
ventricle (AV3V) region in awake rats were also investigated. In male Holtzman rats, pilocarpine (0.04 to
4 μmol/kg b.w.) i.v. induced transitory hypotension followed by long lasting hypertension. Sympathetic
blockade with prazosin (1 mg/kg b.w.) i.v. or AV3V lesions (1 day) almost abolished the pressor response to i.
v. pilocarpine (2 μmol/kg b.w.), whereas the vasopressin antagonist (10 μg/kg b.w.) i.v. reduced the response
to pilocarpine. Pilocarpine (2 and 4 μmol/kg b.w.) i.v. increased the number of c-fos immunoreactive cells in
the subfornical organ, paraventricular and supraoptic nuclei of the hypothalamus, organ vasculosum of the
lamina terminalis, median preoptic nucleus, nucleus of the solitary tract and caudal and rostral ventrolateral
medulla. These data suggest that i.v. pilocarpine activates speciﬁc forebrain and brainstem mechanisms
increasing sympathetic activity and vasopressin secretion to induce pressor response.gy and Pathology, School of
aitá 1680, Araraquara, 14801-
01 6488.
.
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Peripheral treatment with muscarinic cholinergic agonists usually
produces vasodilation and reduction in arterial pressure (Feigl, 1975;
Inoue et al., 1984), whereas central muscarinic cholinergic mecha-
nisms predominantly increase arterial pressure due to increases in
sympathetic activity and vasopressin secretion (Hoffman et al., 1977;
Punnen et al., 1986; Giuliano et al., 1989; Imai et al., 1989; Arneric et
al., 1990; Buccafusco, 1996; Kubo et al., 2000; Padley et al., 2007).
Cholinergic muscarinic agonists like pilocarpine are usually used
as therapeutic agent to stimulate salivary secretion in patients with
xerostomia (Ferguson, 1993). Besides salivation, in anesthetized rats,
small doses of pilocarpine injected intraperitoneally (i.p.) induce a
long-lasting pressor response (Trendelenburg, 1961; Moreira et al.,
2003; Takakura et al., 2005). Injection of pilocarpine directly in the
central nervous system (CNS) induces an intense vasoconstriction inthe mesenteric vascular bed and an increase in arterial pressure
(Moreira et al., 2003). Lesions of the tissue surrounding the
anteroventral portion of the third ventricle (AV3V region) abolish
peripheral pilocarpine-induced pressor responses in anesthetized
rats, suggesting that pilocarpine acts on the central cholinergic
receptors to produce at least part of its cardiovascular responses
(Takakura et al., 2005; Borella et al., 2008).
The AV3V region that includes the organ vasculosum of the lamina
terminalis (OVLT), the preoptic periventricular area, the median
preoptic nucleus (MnPO), and the anterior hypothalamic periven-
tricular area is strongly involved in ﬂuid-electrolyte balance and
cardiovascular regulation (Brody et al., 1978; Brody and Johnson,
1980; Menani et al., 1990). The AV3V region plays a critical role in the
increase in blood pressure and vasopressin release elicited by
injection of angiotensin II (Johnson et al., 1978). Electrolytic lesions
of this region abolish the development of different forms of exper-
imental hypertension like renin-dependent-Goldblatt-hypertension,
hypertension in Dahl salt-sensitive rats and hypertension by the
treatment with deoxycorticosterone and salt (Buggy et al., 1977;
Brody et al., 1978; Brody and Johnson, 1980; Goto et al., 1982;
Haywood et al., 1983). The pressor, dipsogenic, natriuretic and
kaliuretic responses to central cholinergic activation are also strongly
affected by AV3V lesions (Menani et al., 1990; Colombari et al., 1992a,
b; Gonçalves et al., 1992).
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nervous system is due to activation of different nuclei that control
efferent mechanisms like vasopressin secretion and/or sympathetic
system. A previous study using c-fos as a marker of neuronal activity
suggested the involvement of different forebrain areas like the
subfornical organ (SFO), MnPO, OVLT and, perhaps, paraventricular
(PVN) and supra-optic (SON) nuclei of the hypothalamus on peripheral
pilocarpine-induced water intake (Inenaga et al., 2008). Activation of
these areas might also be the mechanism involved in the pressor
responses to peripheral pilocarpine. However, the dose of pilocarpine
used in the previous study (12 μmol/kg of body weight) is higher than
the ones (2 and 4 μmol/kg of body weight) that has been used to
produce pressor response and salivation (Moreira et al., 2003; Takakura
et al., 2005; Borella et al., 2008). Thus, the central areas and efferent
mechanisms activated by small doses of pilocarpine injected peripher-
ally are not clear yet. Therefore, in the present study, we sought to
investigate: 1) the effects of different doses of intravenous (i.v.)
pilocarpine on mean arterial pressure (MAP) and heart rate (HR) in
conscious rats and compared these effects with those of another
muscarinic cholinergic agonist (carbachol) also injected i.v. at similar
doses to reinforce how speciﬁc and particular are the cholinergic
mechanisms activated by peripheral pilocarpine; 2) the importance of
sympathetic activation and vasopressin secretion for i.v. pilocarpine-
induced pressor responses; and 3) the neural activity revealed by c-fos
expression in central areas related to cardiovascular regulation, like the
SFO, PVN, SON, OVLT, MnPO, nucleus of the solitary tract (NTS) and
caudal (CVLM) and rostral (RVLM) ventrolateral medulla in rats treated
with low doses of i.v. pilocarpine. Although a previous study (Takakura
et al., 2005) showed that acute AV3V lesions abolish the pressor
responses to low dose of pilocarpine i.p. in anesthetized rats, to exclude
any possible difference between anesthetized and awake rats, in the
present study, we tested the effects of AV3V lesions on cardiovascular
responses to i.v. pilocarpine in awake rats.
2. Methods
2.1. Animals
Experiments were performed in adult male Holtzman rats
weighing 300 to 320 g. The animals were housed individually in
stainless steel cages in a roomwith controlled temperature (23±2 °C)
and humidity (55±10%). Lights were on from 7:00 am to 7:00 pm.
Standard Guabi rat chow (Paulinia, SP, Brazil) and tap water were
available ad libitum. All experimental protocols were approved by
Animal Experimentation Ethics Committee of the Federal University
of São Paulo (UNIFESP).
2.2. Arterial pressure and heart rate recordings
To record mean arterial pressure (MAP) and heart rate (HR), one
day before the experiments, rats were anesthetized with ketamine
(80 mg/kg of body weight) combined with xylazine (7 mg/kg of body
weight) and a polyethylene tubing (PE-10 connected to a PE-50) was
inserted into the abdominal aorta through the femoral artery. At the
same time, a second polyethylene tubing was inserted in the femoral
vein for drugs administration. Arterial and venous catheters were
tunneled subcutaneously and exposed on the back of the rat to allow
access in unrestrained freely moving rats. To record pulsatile arterial
pressure,MAP andHR, the arterial catheterwas connected to a Stathan
Gould (P23Db) pressure transducer coupled to a pre-ampliﬁer (model
ETH-200 Bridge Bio Ampliﬁer) that was connected to a Powerlab
computer data acquisition system (Powerlab 16SP, ADInstruments).
Recordings were performed 1 day after the surgery and began 10–
15 min after the connection of the arterial line to the pressure
transducer. MAP and HR values recorded immediately before and
those recorded at the maximum peak of change after i.v. injections ofsaline, pilocarpine or carbachol were used as reference to calculate the
changes in MAP and HR.
2.3. Drugs
Pilocarpine (0.04, 0.4, 2 and 4 μmol/kg of body weight), carbachol
(2 and 4 μmol/kg of body weight), prazosin (1 mg/kg of body weight),
[β-Mercapto-β-, β-cyclopentamethylenepropionyl, O-me-Tyr2, Arg8]
vasopressin — Manning Compound (10 μg/kg of body weight) were
purchased from Sigma Chemical Co. (St. Louis, MO, USA). All drugs
were dissolved in sterile saline.
2.4. Immunohistochemical procedure for c-fos detection
All histology was performed using brain tissue from rats deeply
anesthetized with sodium thiopental (70 mg/kg of body weight) and
perfused transcardially with 100 ml of buffered saline followed by
500 ml of freshly prepared 4% paraformaldehyde in 100 mM phos-
phate buffer, pH 7.4. Brains were removed and stored in the perfusion
ﬁxative for 24–48 h at 4 °C before being cut into 40-μm-thick coronal
slices. Tissue was kept in cryoprotectant solution (20% glycerol plus
30% ethylene glycol in 50 mM phosphate buffer, pH 7.4) at −20 °C
until processed.
Immunohistochemistry was processed with anti-fos serum raised
in rabbit (Ab-5, lot D09803; Oncogene Science) at a dilution of
1:10,000. The primary antiserumwas localized using a variation of the
avidin–biotin complex system (ABC). In brief, sections were ﬁrstly
incubated for 24 h in the primary antibody, before the incubation for
90 min at room temperature in a solution of biotinylated goat anti-
rabbit IgG (Vector Laboratories). Then the sections were placed in the
mixed avidin–biotin–horseradish peroxidase complex solution (ABC
Elite kit; Vector Laboratories) for the same period of time. Between
each step of the above immunohistochemistry processing sections
were rinsed 3×10 min with potassium–PBS. The peroxidase complex
was visualized by a 10 min exposure to a chromogen solution
containing 0.02% 3,3′ diaminobenzidine tetrahydrochloride with
0.3% nickel–ammonium sulfate (DAB–Ni) in 0.05 M Tris buffer, pH
7.6, followed by incubation for 10 min in chromogen solution with
hydrogen peroxide (1:3000) to produce a blue-black product. The
reaction was stopped by extensive washing in potassium–PBS, pH 7.4.
At the end, sections were mounted on gelatin-coated slides and then
dehydrated and coverslipped with DPX.
Counts of the number of fos-immunoreactive neurons as a function
of experimental status were generated for each area (OVLT, MnPO,
SFO, SON, PVN, NTS, CVLM and RVLM) by using the 10× objective of a
Zeiss Axioskop 2 microscope (Oberkochen, Germany) equipped with
a camera lucida. To be considered as positive for fos-like immunore-
activity, the nucleus of the neurons had to be of appropriate size
(ranging approximately from 8 to 15 μm) and shape (oval or round),
show the characteristic blue-black staining of oxidized DAB–Ni, and
be distinct from the background at magniﬁcation of 10×. For each
animal, fos-positive cells were plotted and counted at three distinct
rostrocaudal levels of each area (OVLT, MnPO, SFO, SON, PVN, NTS,
CVLM and RVLM).
The number of c-fos-positive nucleus was identiﬁed and counted
in a one-in-six series of transverse sections (1 section every 240 μm).
Counts were made on both sides of the brain and throughout the
portion of the forebrain and brainstem. Summing up the cells
identiﬁed at all levels of the region of interest in the forebrain and in
the brainstem and multiplying this number by 6 produced an
uncorrected total number of c-fos-positive neurons counted in each
rat. After applying a 0.81 Abercrombie correction factor previously
determined on identically prepared histological material (Takakura
et al., 2008), a more accurate estimate of the actual number of c-fos-
positive neurons in the three rat groups was obtained.
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Rats were anesthetized with ketamine (80 mg/kg of body weight)
combined with xylazine (7 mg/kg of body weight) and placed in a
stereotaxic frame (model 900, David Kopf Instruments). Bregma and
lambda were positioned at the same horizontal level. A tungsten wire
electrode (0.4 mm in diameter), bared at the tip (0.5 mm), was
inserted into the brain using the following coordinates: 0.0 mm from
bregma, in the midline and 7.0 mm below the dura mater. Electrolytic
lesionswere performed using a cathodal current (2 mA during 10 s). A
clip attached to the tail was used as the indifferent electrode. Sham-
lesioned rats had the electrode placed along the same coordinates,
except that no current was passed.
To avoid acute adipsia that follows AV3V lesions (Buggy et al.,
1977), besides water and food pellets, AV3V-lesioned rats had access
to 10% sucrose solution during 5 days following the lesions. From a
total of 22 rats submitted to AV3V lesions, 13 rats had lesions placed
correctly.2.6. Histology to conﬁrm AV3V lesions
At the end of the experiments, the animals were deeply
anesthetized with sodium thiopental (70 mg/kg of body weight, i.
p.). Saline followed by 10% buffered formalin was perfused through
the heart. The brains were removed, frozen, cut coronally into 50 μm
sections, stained with Giemsa stain and analyzed by light microscopy
to conﬁrm the AV3V lesions.2.7. Statistical analysis
Statistical analysis was done with Sigma Stat version 3.0 (Jandel
Corporation, Point Richmond, CA). Data are reported as means±
standard error of means (SEM). One-way parametric analysis of
variance followed by the Newman Keuls multiple comparisons test
was used. The hypotensive and hypertensive responses to i.v.
pilocarpine were analyzed separately. Signiﬁcance was set at pb0.05.3. Experimental protocols
3.1. MAP and HR in conscious rats that received i.v. pilocarpine or
carbachol
Baseline MAP and HR were recorded for 10 min and then rats
received i.v. injections of saline (control). Ten minutes later, rats
received i.v. injections of pilocarpine (0.04, 0.4, 2 or 4 μmol/kg of
body weight) or carbachol (2 or 4 μmol/kg of body weight) and
the recordings continued for an additional 40 min. Each dose of
pilocarpine or carbachol was tested in one group of animals.Fig. 1. Changes in (A) mean arterial pressure (MAP) and (B) heart rate (HR) produced
by different doses of pilocarpine (0.04, 0.4, 2 and 4 μmol/kg of body weight) injected
intravenously in conscious rats. The results are represented as mean±SEM. n=8 rats/
group. *Different from saline (Newman–Keuls test, pb0.05).3.2. MAP and HR in conscious rats that received i.v. pilocarpine
combined with i.v. prazosin or vasopressin antagonist
Baseline MAP and HR were recorded for 10 min and then rats
received i.v. injections of saline, prazosin (1 mg/kg of body weight)
or vasopressin V1 receptor antagonist (10 μg/kg of body weight).
Fifteen min later rats received i.v. injections of pilocarpine
(2 μmol/kg of body weight) and the recordings continued for an
additional 40 min. Different groups of rats were used to test each
combination of treatments. The dose of pilocarpine used to test the
effects of the pre-treatment with prazosin or vasopressin antagonist
was the smallest dose that injected i.v. produced strong effects on
MAP.3.3. Expression of c-fos in forebrain and brainstem areas in conscious
rats treated with i.v. pilocarpine
The expression of c-fos in different central areas (SFO, MnPO,
OVLT, PVN, SON, NTS, CVLM and RVLM) was investigated in three
groups of conscious rats. A control group (n=4) received i.v.
injections of saline, another group (n=4) received i.v. injections of
pilocarpine (2 μmol/kg of body weight) and a third group (n=5)
received i.v. injections of pilocarpine (4 μmol/kg of body weight).
Sixtymin after the i.v. injections, rats were anesthetized, perfused and
had the brains removed and submitted to immunohistochemical
procedures for c-fos detection. Each rat was assigned a random letter
code and the cells were counted by a ‘blinded’ observer.
3.4. MAP and HR in conscious AV3V-lesioned rats that received i.v.
pilocarpine
MAP and HR were tested in conscious rats with acute (1 day) or
chronic (15 days) sham or electrolytic AV3V lesions. Baseline MAP
and HR were recorded for 10 min and then the rats received i.v.
injections of saline (control). Ten minutes later rats received i.v.
injections of pilocarpine (2 μmol/kg of body weight) and the
recordings continued for an additional 40 min. The dose of pilocarpine
used to test the effects of AV3V lesions was the smallest dose that
injected i.v. produced strong effects on MAP in awake rats.
4. Results
4.1. Cardiovascular effects of pilocarpine or carbachol i.v. in conscious
rats
Pilocarpine (0.04, 0.4, 2 and 4 μmol/kg of body weight) i.v. induced
an immediate and transitory (less than 10 s of duration) hypotension
Table 1
Changes in MAP and HR produced by i.v. injections of saline or carbachol in conscious
rats.
Treatment Changes in MAP (mm Hg) Changes in HR (bpm)
Saline +4±3 +10±6
Carbachol (2 μmol/kg) −25±4* −208±14*
Carbachol (4 μmol/kg) −33±6* −214±19*
Values are mean±SEM. Carbachol (2 and 4 μmol/kg of body weight). *Signiﬁcantly
different from saline. n=6 rats/group.
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saline: 2±3 mm Hg) [F(7, 66)=46.54; pb0.01] followed by long
lasting (around 30 min duration) pressor responses (8±2, 10±2,
65±2 and 73±2 mm Hg, respectively, vs. saline: 2±3 mm Hg)
[F(7, 66)=54.12; pb0.01] (Fig. 1A). Pilocarpine (2 and 4 μmol/kg
of body weight, i.v.) also increased HR (25±8 and 70±9 bpm,
respectively, vs. saline: 8±5 bpm) [F(7, 66)=23.75; pb0.01] (Fig. 1B).
Carbachol (2 and 4 μmol/kg of body weight) induced only a fast
(less than10 s of duration) hypotension (−25±4and−33±6 mmHg,
respectively, vs. saline: 4±3 mm Hg) [F(2, 18)=22.37; pb0.01]
(Table 1). Carbachol also decreased HR in conscious rats (−208±14
and−214±19 bpm, respectively, vs. saline: 10±6) [F(2, 12)=18.49;
pb0.01] (Table 1).4.2. Cardiovascular effects to i.v. pilocarpine combined with i.v. prazosin
or vasopressin antagonist in conscious rats
The pre-treatment with i.v. vasopressin V1 antagonist (Manning
Compound, 10 μg/kg of body weight) reduced the pressor response to
pilocarpine (2 μmol/kg of body weight) i.v. (37±8 mm Hg, vs. saline:
62±5 mm Hg), whereas the α1 adrenoceptor antagonist prazosin
(1 mg/kg of body weight) almost abolished the pressor response to
pilocarpine i.v. (12±3 mm Hg) [F(3, 26)=45.72; pb0.01] (Fig. 2A).
Prazosin or vasopressin V1 antagonist did not affect i.v. pilocarpine-
induced hypotension and tachycardia (Fig. 2A and B).
Prazosin (1 mg/kg of body weight) i.v. abolished the response to i.
v. injection of the α1-adrenoceptor agonist phenylephrine (5 μg/kg of
body weight, i.v.) and the vasopressin antagonist (10 μg/kg of body
weight, i.v.) abolished the pressor response to vasopressin
(12 ng/0.1 ml, i.v.) (data not shown).Fig. 2. Changes in (A) mean arterial pressure (MAP) and (B) heart rate (HR) produced by p
prazosin (1 mg/kg of body weight) or vasopressin V1 antagonist (Manning Compound — 10
n=8 rats/group. *Different from saline+pilocarpine (Student–Newman–Keuls test, pb0.04.3. Expression of c-fos in the forebrain and brainstem areas of conscious
rats treated with i.v. pilocarpine
Pilocarpine (2 and 4 μmol/kg of body weight) i.v. increased the
number of c-fos imunorreactive cells in the OVLT [F(2, 14)=21.35;
pb0.05], MnPO [F(2, 14)=31.54; pb0.05], SFO [F(2, 14)=26.17;
pb0.05], SON [F(2, 14)=56.11; pb0.01], PVN [F(2, 14)=64.78;
pb0.01], dorsomedial NTS [F(2, 11)=31.24; pb0.01], commissural
NTS [F(2, 11)=36.61; pb0.01], CVLM [F(2, 11)=26.61; pb0.01] and
RVLM [F(2, 11)=9.27; pb0.05] (Figs. 3 and 4).
4.4. Cardiovascular effects to i.v. pilocarpine in conscious AV3V-lesioned
rats
As shown by previous studies (Vieira et al., 2004, 2006; Takakura
et al., 2005), AV3V lesions (1 and 15 days) had no effect on resting
MAP (113±4 and 115±4 mm Hg, respectively, vs. sham lesions:
110±6 and 113±6 mm Hg, respectively), however, AV3V lesions
(1 day) increased resting HR (455±18 bpm, vs. sham lesion: 315±
9 bpm).
One day AV3V-lesion almost abolished the pressor response to
pilocarpine (2 μmol/kg of body weight) i.v. (7±5 mm Hg, vs. sham:
63±6 mm Hg), [F(5, 32)=27.55; pb0.01] without changing the
tachycardic response (Fig. 5). The initial hypotension to i.v. pilocar-
pine was not modiﬁed by 1 day AV3V lesion, except that it had a
longer duration (around 40 s vs. sham: 4 s).
The pressor and tachycardic response to i.v. pilocarpine was not
modiﬁed by 15-day AV3V lesion (Fig. 5).
The AV3V lesion was located between the anterior commissure
and the ﬂoor of the third ventricle with bilateral damage of the
periventricular tissues from the organum vasculoso of the lamina
terminalis through the preoptic and anterior hypothalamus, never
extending caudally to the arcuate nucleus or medial hypothalamus
(Brody et al., 1978; Menani et al., 1990; Vieira et al., 2004, 2006;
Takakura et al., 2005). Fig. 6 shows a typical AV3V lesion in one rat
representative of the lesioned group.
5. Discussion
Similar to anesthetized rats, pilocarpine injected i.v. produced a
dose-dependent and transitory hypotension followed by hyperten-
sion in conscious rats (Trendelenburg, 1961; Moreira et al., 2003;ilocarpine (2 μmol/kg of body weight) before and after intravenous administration of
mg/kg of body weight) in conscious rats. The results are represented as means±SEM.
5).
Fig. 3. (A, B, C, D, E and F) photomicrographs showing c-fos expression in (A and B)MnPO, (C and D) PVN and (E and F) SON in rats representative of the rats treated with intravenous
injection of (A, C and E) saline or (B, D and F) pilocarpine (4 μmol/kg of body weight). (G) Number of c-fos immunoreactive cells in forebrain areas in rats treated with intravenous
injection of saline or pilocarpine (2 and 4 μmol/kg of body weight). Results in panel G are expressed asmeans±SEM. n=4–5 rats/group. *Different from saline (Newman–Keuls test,
pb0.05). Scale bar: 0.5 mm in E, applies to all panels. Abbreviations: AC, anterior commissure; MnPO, median preoptic nucleus; Opt, optic tract; OVLT, organ vasculosum of the
lamina terminalis; PVN, paraventricular nucleus; SFO, subfornical organ; SON, supra optic nucleus; 3 V, third ventricle.
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body weight) i.v. produced an intense and long-lasting pressor
response and tachycardia. The pressor response to pilocarpine i.v.
was almost abolished by the blockade of peripheral α1-adrenoceptors
with prazosin or acute (1 day) AV3V lesions, whereas the antagonism
of vasopressin V1 receptors only reduced this response. These low
doses of pilocarpine injected i.v. also activated forebrain areas (MnPO,OVLT, SFO, SON and PVN) and the NTS, similarly to the results of a
previous study that investigated the effects of a higher dose of
pilocarpine (Inenaga et al., 2008). In addition, the present results
expand the conclusion of the previous study showing that pilocarpine
i.v. also activated the RVLM and CVLM. Therefore, peripheral
pilocarpine acting centrally activates forebrain and brainstem areas
to induce pressor responses that result from increased vasopressin
Fig. 4. (A, B, C, D, E, F, G and H) photomicrographs showing c-fos expression in (A and B) commissural NTS, (C and D) dorsomedial NTS (E and F) CVLM and (G and H) RVLM in rats
representative of the rats treated with intravenous injection of (A, C, E and G) saline or (B, D, F and H) pilocarpine (4 μmol/kg of body weight). (I) Number of c-fos immunoreactive
cells in brainstem areas in rats treated with intravenous injection of saline or pilocarpine (2 and 4 μmol/kg of body weight). Results in panel I are expressed as means±SEM. n=4–5
rats/group. *Different from saline (Newman–Keuls test, pb0.05). Scale bar: 0.5 mm in H, applies to all panels. Abbreviations: Amb, nucleus ambiguous; AP, area postrema; cc, central
canal; CVLM, caudal ventrolateral medulla; Gr, gracilis nucleus; lin, linearis nucleus; LRN, lateral reticular nucleus; cNTS, commissural nucleus of the solitary tract; dmNTS,
dorsomedial nucleus of the solitary tract; RVLM, rostral ventrolateral medulla; sol, solitary tract; XII, hypoglossal nucleus.
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Fig. 5. Changes in (A) mean arterial pressure (MAP) and (B) heart rate (HR) produced by the treatment with pilocarpine (2 μmol/kg of body weight) or saline injected i.v. in 1 or
15 day sham or AV3V-lesioned rats. The results are represented as means±SEM. n=7 rats/group. *Different from sham+saline (Student–Newman–Keuls test, pb0.05).
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dependent mechanism. The pressor response produced by pilocarpine
leads to baroreﬂex activation and thus the activation of NTS and CVLM
as revealed by c-fos immunoreactivity.
The initial hypotension to i.v. pilocarpine is probably a result of the
vasodilation produced by the peripheral action of pilocarpine before it
access to the CNS areas that activate pressor mechanisms (sympa-
thetic activation and vasopressin secretion) which overcome periph-
eral vasodilation inducing pressor responses. Differently from
pilocarpine, other cholinergic muscarinic agonists like carbachol
injected peripherally produce only peripheral effects (hypotension
and intense bradycardia) (Inoue et al., 1984). Therefore, due to some
particular characteristics, pilocarpine easily crosses the blood-brain
barrier (Freedman et al., 1989), reaching central areas to produce
pressor responses.
As suggested by the present results, pilocarpine-induced pressor
response is dependent on sympathetic activation and vasopressin
secretion similar to previous reports for the activation of central
muscarinic receptors (Hoffman et al., 1977; Imai et al., 1989). A
previous study suggested that sympathetic activation might be the
result of a ganglionic action of i.v. pilocarpine (Trendelenburg, 1961),
whereas other studies have suggested a central action of low doses of
pilocarpine to produce pressor response (Takakura et al., 2005;
Borella et al., 2008). The present results show that low doses of
pilocarpine increase the number of c-fos immunoreactive cells in
central areas involved in the control of sympathetic activity and
vasopressin secretion like the MnPO, OVLT, SFO, SON, PVN, and RVLM.
Pilocarpine also increased the number of c-fos immunoreactive
neurons in the NTS and CVLM that together with the RVLM are the
main areas of the brainstem circuitry related to cardiovascular control
(Ciriello et al., 1994; Dampney, 1994; Guyenet, 2006). Pilocarpine
strongly increases arterial pressure which activates baroreceptors,
thereby enhancing the activity of NTS and CVLM neurons, before the
release of inhibitory signals in the RVLM trying to reduce sympathetic
activation. In spite of the activation of these inhibitory mechanisms,
arterial pressure increases as a consequence of the strong activation of
pressor mechanisms due to direct or indirect activation of RVLM,
AV3V region, PVN and SON by pilocarpine.
The increase of c-fos immunoreactive cells in the AV3V region
(OVLT and MnPO) in rats treated with i.v. pilocarpine suggests that
this region is involved in the responses produced by peripheral
pilocarpine. The effects of AV3V lesions abolishing the pressor
responses to pilocarpine conﬁrm that mechanisms present in theAV3V region are essential for pilocarpine-induced pressor response.
Pilocarpine i.v. also increases c-fos expression in the SFO, an area
strongly connected with the AV3V region (Brody et al., 1978; Brody
and Johnson, 1980). Injection of pilocarpine directly into the SFO
activates neurons in this area (Inenaga et al., 2008) and cholinergic
activation of the SFO produces strong pressor response dependent on
the AV3V region (Colombari et al., 1992a). Therefore, pilocarpine may
activate the AV3V region directly or indirectly (through the action in
the SFO). Connections between the AV3V region and the PVN or SON
may also be involved in the control of vasopressin secretion induced
by pilocarpine, whereas sympathetic activation may involve mainly
descending connections from the AV3V region to brainstem areas
through the PVN that in turn may also connect directly to the
intermediolateral column (IML) (Knuepfer et al., 1984; Yang and
Coote, 1998; Westerhaus and Loewy, 1999; Geerling et al., 2010).
Differently from the AV3V region, a previous study showed that the
MSA is not involved in the pressor response to i.v. pilocarpine (Paulin
et al., 2009) and, interestingly in the present study, no increase in c-
fos expression in the MSA was detected (data not shown).
Acute AV3V lesions abolished the pressor responses to i.v.
pilocarpine, whereas the hypotension was not affected, which
suggests that these lesions impair the central pressor mechanisms
activated by pilocarpine leaving intact the peripheral mechanisms
responsible for the hypotension. In the absence of the central pressor
mechanisms, long lasting hypotensive responses were expected due
to activation of peripheral mechanisms alone. However, although
longer (37 s in AV3V-lesioned rats, vs. 4 s in sham) the hypotension to
i.v. pilocarpine in AV3V-lesioned rats was still transitory, followed by
the return of arterial pressure close to baseline levels. These results
suggest that pressor mechanisms are still partially acting in acute
AV3V-lesioned rats and the action of these mechanisms is enough to
counterbalance the peripheral vasodilation, reducing the duration of
hypotension. In chronic AV3V-lesioned rats, the pressor responses to i.
v. pilocarpine are completely recovered, which suggests that the
central pressor mechanisms are activated by i.v. pilocarpine in these
rats. The neural plasticity is probably the mechanism involved in the
recovery of the central effects of pilocarpine in chronic AV3V-lesioned
rats.
Although pilocarpine-induced salivation is suggested to depend on
activation of central mechanisms (Moreira et al., 2001, 2002;
Takakura et al., 2003, 2009; Borella et al., 2008), similar to a previous
study (Inenaga et al., 2008) no increase in the number of c-fos
immunoreactive cells in the salivary nuclei of the brainstem was
Fig. 6. Photomicrograph showing the typical AV3V lesion (arrows). AC, anterior
commissure. Scale: 1 mm.
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evidence in the literature suggesting that peripheral pilocarpine-
induced salivation involves the activation of the salivary nuclei in the
brainstem. Therefore, it seems that pilocarpine increases salivary
gland secretion acting in other brain regions that might be even the
areas investigated in the present study related to cardiovascular
control.
In summary, i.v. pilocarpine, differently from carbachol, produces a
transitory hypotension probably due to its peripheral action followed
by sustained hypertension dependent on its central action in the
forebrain (MnPO, OVLT, SFO, SON and PVN) and brainstem areas
(RVLM) increasing vasopressin secretion and mainly sympathetic
activation through an AV3V-dependent mechanism. Therefore, the
efﬁciency of pilocarpine as a therapeutic agent to correct salivary
gland dysfunction compared to other cholinergic muscarinic agonists
is probably the result of a combination of salivary gland stimulation
together with efﬁcient maintenance of arterial pressure due to a
balance between two opposite mechanisms: peripheral hypotensive
and central hypertensive mechanisms activated by pilocarpine.
However, on the other side, it is necessary to consider a possible
hypertensive effect of this treatment.
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